RAFFA WEALTH MANAGEMENT, LLC’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-378
Closed -$10.1K 1159
2024
Q2
$10.1K Hold
378
﹤0.01% 438
2024
Q1
$12.9K Buy
+378
New +$11.3K ﹤0.01% 384
2017
Q3
Sell
-41
Closed -$1.77K 379
2017
Q2
$1.77K Hold
41
﹤0.01% 296
2017
Q1
$1.28K Hold
41
﹤0.01% 305
2016
Q4
$1.03K Hold
41
﹤0.01% 428
2016
Q3
$1.01K Hold
41
﹤0.01% 412
2016
Q2
$835 Hold
41
﹤0.01% 455
2016
Q1
$625 Hold
41
﹤0.01% 590
2015
Q4
$551 Hold
41
﹤0.01% 646
2015
Q3
$575 Hold
41
﹤0.01% 606
2015
Q2
$696 Buy
+41
New +$584 ﹤0.01% 520

Other funds holding SUPN

RAFFA WEALTH MANAGEMENT, LLC's SUPN Position: Q3 2024 in Review

RAFFA WEALTH MANAGEMENT, LLC sold out of Supernus Pharmaceuticals (SUPN) in Q3 2024, closing a stake of 378 shares — an estimated $10.1K sold.

RAFFA WEALTH MANAGEMENT, LLC first reported a position in SUPN in Q2 2015 and held it in 11 quarters. The position peaked at $12.9K in Q1 2024. 273 funds tracked by Wall St. Rank hold SUPN as of Q3 2024.

  • RAFFA WEALTH MANAGEMENT, LLC reported no remaining Supernus Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • RAFFA WEALTH MANAGEMENT, LLC sold 378 Supernus Pharmaceuticals shares in Q3 2024, an estimated $10.1K.
  • RAFFA WEALTH MANAGEMENT, LLC first reported a position in Supernus Pharmaceuticals in Q2 2015 and held it in 11 quarters.
  • RAFFA WEALTH MANAGEMENT, LLC's Supernus Pharmaceuticals position peaked at $12.9K in Q1 2024.
  • 273 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2024.

Based on RAFFA WEALTH MANAGEMENT, LLC's 13F filing for Q3 2024, filed 27 Jul 2026.